Want to see HK:2348 full AI Analyst Report?
Total Valuation
Dawnrays Pharmaceutical Holdings Ltd. has a market cap or net worth of HK$1.39B. The enterprise value is -HK$300.73M.
Market CapHK$1.39B
Enterprise Value-HK$300.73M
Share Statistics
Dawnrays Pharmaceutical Holdings Ltd. has 1,507,025,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,507,025,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Dawnrays Pharmaceutical Holdings Ltd.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.40%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.40%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.15M
Profits Per Employee232.41K
Employee Count1,074
Asset Turnover0.31
Inventory Turnover3.12
Valuation Ratios
The current PE Ratio of Dawnrays Pharmaceutical Holdings Ltd. is 5.1. Dawnrays Pharmaceutical Holdings Ltd.’s PEG ratio is -0.12.
PE Ratio5.1
PS Ratio1.34
PB Ratio0.49
Price to FCF6.98
Price to Operating Cash Flow3.12
PEG Ratio-0.12
Income Statement
In the last 12 months, Dawnrays Pharmaceutical Holdings Ltd. had revenue of 1.23B and earned 213.97M in profits. Earnings per share was 0.14.
Revenue1.23B
Gross Profit557.40M
Operating Income229.65M
Pretax Income249.61M
Net Income213.97M
EBITDA347.57M
Earnings Per Share (EPS)0.14
Cash Flow
In the last 12 months, operating cash flow was 376.95M and capital expenditures -78.86M, giving a free cash flow of 298.09M billion.
Operating Cash Flow376.95M
Free Cash Flow298.09M
Free Cash Flow per Share0.20
Dividends & Yields
Dawnrays Pharmaceutical Holdings Ltd. pays an annual dividend of HK$0.015, resulting in a dividend yield of 6.85%
Dividend Per ShareHK$0.015
Dividend Yield6.85%
Payout Ratio36.39%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.27
52-Week Price Change-18.58%
50-Day Moving Average0.97
200-Day Moving Average1.03
Relative Strength Index (RSI)39.48
Average Volume (3m)477.33K
Important Dates
Dawnrays Pharmaceutical Holdings Ltd. upcoming earnings date is Mar 19, 2027, TBA (Confirmed).
Last Earnings DateAug 28, 2026
Next Earnings DateMar 19, 2027
Ex-Dividend Date―
Financial Position
Dawnrays Pharmaceutical Holdings Ltd. as a current ratio of 4.64, with Debt / Equity ratio of 0.13%
Current Ratio4.64
Quick Ratio4.21
Debt to Market Cap0.05
Net Debt to EBITDA-3.13
Interest Coverage Ratio463.00
Taxes
In the past 12 months, Dawnrays Pharmaceutical Holdings Ltd. has paid 38.51M in taxes.
Income Tax38.51M
Effective Tax Rate0.15
Enterprise Valuation
Dawnrays Pharmaceutical Holdings Ltd. EV to EBITDA ratio is 1.61, with an EV/FCF ratio of 2.37.
EV to Sales0.45
EV to EBITDA1.61
EV to Free Cash Flow2.37
EV to Operating Cash Flow1.57
Balance Sheet
Dawnrays Pharmaceutical Holdings Ltd. has HK$1.59B in cash and marketable securities with HK$4.48M in debt, giving a net cash position of HK$1.59B billion.
Cash & Marketable SecuritiesHK$1.59B
Total DebtHK$4.48M
Net CashHK$1.59B
Net Cash Per ShareHK$1.05
Tangible Book Value Per ShareHK$1.91
Margins
Gross margin is 47.81%, with operating margin of 18.66%, and net profit margin of 17.38%.
Gross Margin47.81%
Operating Margin18.66%
Pretax Margin20.28%
Net Profit Margin17.38%
EBITDA Margin28.24%
EBIT Margin18.48%
Analyst Forecast
The average price target for Dawnrays Pharmaceutical Holdings Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast6.55%
EPS Growth Forecast36.62%